Literature DB >> 10792446

Seizures induce widespread upregulation of cystatin B, the gene mutated in progressive myoclonus epilepsy, in rat forebrain neurons.

E D'Amato1, Z Kokaia, A Nanobashvili, M Reeben, A E Lehesjoki, M Saarma, O Lindvall.   

Abstract

Loss of function mutations in the gene encoding the cysteine protease inhibitor, cystatin B (CSTB), are responsible for the primary defect in human progressive myoclonus epilepsy (EPM1). CSTB inhibits the cathepsins B, H, L and S by tight reversible binding, but little is known regarding its localization and physiological function in the brain and the relation between the depletion of the CSTB protein and the clinical symptoms in EPM1. We have analysed the expression of mRNA and protein for CSTB in the adult rat brain using in situ hybridization and immunocytochemistry. In the control brains, the CSTB gene was differentially expressed with the highest levels in the hippocampal formation and reticular thalamic nucleus, and moderate levels in amygdala, thalamus, hypothalamus and cortical areas. Detectable levels of CSTB were found in virtually all forebrain neurons but not in glial cells. Following 40 rapidly recurring seizures evoked by hippocampal kindling stimulations, CSTB mRNA expression showed marked bilateral increases in the dentate granule cell layer, CA1 and CA4 pyramidal layers, amygdala, and piriform and parietal cortices. Maximum levels were detected at 6 or 24 h, and expression had reached control values at 1 week post-seizures. The changes of mRNA expression were accompanied by transient elevations (at 6-24 h) of CSTB protein in the same brain areas. These findings demonstrate that seizure activity leads to rapid and widespread increases of the synthesis of CSTB in forebrain neurons. We propose that the upregulation of CSTB following seizures may counteract apoptosis by binding cysteine proteases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792446     DOI: 10.1046/j.1460-9568.2000.00058.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

1.  In vitro study of stability and amyloid-fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1.

Authors:  Sabina Rabzelj; Vito Turk; Eva Zerovnik
Journal:  Protein Sci       Date:  2005-09-09       Impact factor: 6.725

2.  Role of endoplasmic reticulum stress in the amygdaloid kindling model of rats.

Authors:  Yuri Chihara; Yuto Ueda; Taku Doi; L James Willmore
Journal:  Neurochem Res       Date:  2011-05-22       Impact factor: 3.996

Review 3.  Molecular background of progressive myoclonus epilepsy.

Authors:  Anna-Elina Lehesjoki
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

4.  Pore formation by human stefin B in its native and oligomeric states and the consequent amyloid induced toxicity.

Authors:  Gregor Anderluh; Eva Zerovnik
Journal:  Front Mol Neurosci       Date:  2012-08-02       Impact factor: 5.639

5.  Human stefin B normal and patho-physiological role: molecular and cellular aspects of amyloid-type aggregation of certain EPM1 mutants.

Authors:  Mira Polajnar; Slavko Ceru; Nataša Kopitar-Jerala; Eva Zerovnik
Journal:  Front Mol Neurosci       Date:  2012-08-24       Impact factor: 5.639

6.  Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB.

Authors:  Véronique Brault; Benoît Martin; Nathalie Costet; Jean-Charles Bizot; Yann Hérault
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

7.  Characterization of a rare Unverricht-Lundborg disease mutation.

Authors:  Ana Joana Duarte; Diogo Ribeiro; João Chaves; Olga Amaral
Journal:  Mol Genet Metab Rep       Date:  2015-08-05

8.  Cystatin B is essential for proliferation and interneuron migration in individuals with EPM1 epilepsy.

Authors:  Francesco Di Matteo; Fabrizia Pipicelli; Christina Kyrousi; Isabella Tovecci; Eduardo Penna; Marianna Crispino; Angela Chambery; Rosita Russo; Ane Cristina Ayo-Martin; Martina Giordano; Anke Hoffmann; Emilio Ciusani; Laura Canafoglia; Magdalena Götz; Rossella Di Giaimo; Silvia Cappello
Journal:  EMBO Mol Med       Date:  2020-05-07       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.